On November 12, 2020 Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company, reported that it will present the clinical development schedule for its Sepsis, COVID-19 and Solid Cancer programs during a fireside chat at H.C. Wainwright’s 6th Annual Israel Conference. See below for more details (Press release, Enlivex Therapeutics, NOV 12, 2020, View Source [SID1234570730]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

Event: H.C. Wainwright 6th Annual Israel Conference

Format: Fireside chat (virtual)

Date & Time: Thursday November 12, 10:00 EST.

Webcast Link: View Source

During the fireside chat, company management will provide an update on the clinical and preclinical development of AllocetraTM for the following indications:

Sepsis

·Phase IIb trial in sepsis patients remains on track for initiation in Q4 2020.
·This Phase IIb trial expects to enroll up to 160 patients.
·Interim clinical results are expected in Q3 2021.
COVID-19

·Phase II trial ongoing, interim clinical results expected by year-end 2020.
·Approved vaccines are not expected to eliminate the need for effective COVID-19 treatments.
oAssuming approved vaccines will have an average efficacy of 85%, expected cases of severe and critical COVID-19 are likely to be at 15% of the rate of current severe/critical cases.
oSome of the population may choose to remain unvaccinated.
·Positive Phase II data, if obtained, could potentially open regulatory pathways to initiate clinical trials in other indications associated with organ dysfunction and failure.
Solid Cancers

·Additional preclinical characterization of the mechanism of action of AllocetraTM in solid cancers that have no effective therapies remains ongoing.
·Enlivex is working to establish preclinical and clinical collaborations with leading cancer medical centers in the U.S.

On November 12, 2020 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology and neuroscience, reported the presentation of new preclinical data on its VISTA antagonist antibodies at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 35th Anniversary Annual Meeting, taking place November 9-14, 2020 (Press release, Kineta, NOV 12, 2020, View Source;utm_medium=rss&utm_campaign=kineta-presents-new-preclinical-data-at-the-2020-sitc-annual-meeting-on-its-vista-antagonist-antibodies [SID1234570728]). Thierry Guillaudeux, PhD, Senior Vice President Immuno-oncology at Kineta, will present a poster on the new preclinical data on the company’s fully human anti-VISTA antibodies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"VISTA is a novel immuno-oncology checkpoint that works against myeloid cells, which are a key driver of the immunosuppressive tumor microenvironment" said Thierry Guillaudeux. "I am excited to present these new data on Kineta’s fully human lead antibodies that have demonstrated strong potency and binding against VISTA and offer the potential to become an effective immunotherapy for patients with cancer".

VISTA is a key driver of the immunosuppressive tumor microenvironment (TME) and is overexpressed on myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs). It is a critical myeloid cell immune-checkpoint, and VISTA blockade can reprogram suppressive myeloid cells and reactivate antitumor immune function. Blocking VISTA activates an immune cell cascade that increases T cell effector functions to drive an efficient anti-tumor response. Preclinical studies have demonstrated single agent anti-VISTA activity but also demonstrate that targeting VISTA in combination with PD-1, PD-L1 or CTLA-4 can significantly improve the efficacy of those checkpoint inhibitors.

Presentation Details:

Poster Title: Highly Potent Fully Human anti-VISTA Antibodies: A New Target Checkpoint Inhibitor against Immunosuppressive Myeloid Cells

Date/Time: Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1:00-1:30 p.m. EST

Presenter: Thierry Guillaudeux, PhD

VISTA Publications – Kineta VISTA Poster at SITC (Free SITC Whitepaper)

On November 12, 2020 Incyte (Nasdaq:INCY) reported that it will present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, December 1, 2020 at 10:30 a.m. EST (Press release, Incyte, NOV 12, 2020, View Source [SID1234570726]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 90 days.

On November 12, 2020 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, reported that it will host a virtual Investor Day on November 20, 2020 at 8AM EST/ 1PM GMT (Press release, Adaptimmune, NOV 12, 2020, View Source [SID1234570725]). A link to register is available HERE and further details are on the Investor Relations tab of the Adaptimmune website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company plans to showcase the market potential for its SPEAR T-cell portfolio as well as provide details about its early stage pipeline with multiple cell therapies beyond its current autologous TCR T-cell products. Presentations will be given by Adaptimmune’s Senior Leadership Team in addition to Dr. Dejka Araujo from the Department of Sarcoma Medical Oncology, Division of Cancer Medicine of the MD Anderson Cancer Center.

On November 12, 2020 Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, reported that members of its senior management team will host investor meetings at the at the SVB Leerink Oncology 1×1 Day being held on Thursday, November 19, 2020 (Press release, Replimune, NOV 12, 2020, View Source;1-day [SID1234570703]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!